Brazil Artificial lungs Market Overview, 2031

The artificial lung market in Brazil is witnessing increasing demand due to the rising prevalence of respiratory disorders, including chronic obstructive pulmonary disease COPD, acute respiratory distress syndrome ARDS, pulmonary fibrosis, and the long-term impacts of viral infections, which create a critical need for mechanical respiratory support beyond traditional ventilation and lung transplantation. The market includes a variety of products such as extracorporeal membrane oxygenation ECMO systems, portable and wearable artificial lungs, implantable paracorporeal lung devices, and associated filtration, pump, and monitoring systems, designed to provide temporary or long-term support, improve patient outcomes, and enhance quality of life. Technological innovations are central to market growth, featuring miniaturized oxygenators, biocompatible membranes, AI-assisted sensors, telemedicine-enabled monitoring, and energy efficient pumps that optimize oxygenation, remove carbon dioxide, and allow continuous patient surveillance. Regulatory frameworks under ANVISA govern device approval, quality standards, and clinical use, while healthcare policies and insurance coverage influence adoption and accessibility. Key drivers include increasing respiratory disease incidence, scarcity of donor lungs, expansion of ICU and critical care infrastructure, and growing awareness of advanced life-support solutions. Challenges include high device and procedural costs, need for trained critical-care personnel, technical hurdles in long-term implantation and biocompatibility, and limited availability in rural or semi-urban areas. Core components such as oxygenation membranes, blood pumps, sensors, tubing, and control units support device functionality, ensuring effective gas exchange, patient safety, and monitoring, collectively driving adoption, improving clinical outcomes, and strengthening the ecosystem of artificial lung technologies across Brazil.

According to the research report, "Brazil Artificial lungs Overview, 2031," published by Bonafide Research, the Brazil Artificial lungs is anticipated to grow at more than 9.2% CAGR from 2026 to 2031.In Brazil, the artificial lung market is primarily driven by demand from hospitals, intensive care units ICUs, specialty pulmonary and critical-care centers, and research institutions focused on advanced respiratory support and life-saving interventions for chronic and acute lung conditions, with major urban centers such as São Paulo, Rio de Janeiro, and Brasília leading adoption due to well-established healthcare infrastructure and availability of skilled critical-care specialists. The competitive landscape features global leaders like Medtronic, LivaNova, Xenios, Abiomed, and Getinge, which collaborate with local distributors, hospitals, and academic medical centers to supply ECMO systems, portable and wearable artificial lungs, and implantable devices, while Brazilian companies and distributors contribute through maintenance services, consumables, tubing sets, membranes, and training programs. Business trends indicate a shift toward portable and home-care solutions, AI-assisted monitoring, integration with telemedicine platforms, and development of implantable bioartificial lungs to improve patient quality of life and reduce hospital dependency. Key opportunities exist in expanding access to underserved urban and semi urban regions, upgrading ICU infrastructure, and implementing remote monitoring and integrated care programs. Sales channels include direct procurement by hospitals and clinics, partnerships with distributors, online medical equipment platforms, and collaborations with insurance providers for reimbursement support. Supporting factors such as ANVISA regulatory approvals, clinical training programs for staff, awareness campaigns for patients and caregivers, and advanced monitoring systems enhance device adoption and utilization. Continuous innovation in core components such as oxygenation membranes, pumps, sensors, control units, and filtration systems, combined with clinical support, drives market growth, improves patient outcomes, and strengthens Brazil’s artificial lung ecosystem.

In Brazil, the artificial lung market is segmented by technology type, encompassing extracorporeal membrane oxygenation ECMO systems, artificial lung devices, heart-lung machines, bioengineered lung tissues, membrane oxygenators, and ventricular assist devices with integrated oxygenation, each serving specific clinical needs and applications. ECMO systems dominate in critical care and intensive care units, providing temporary life-saving support for patients with acute respiratory distress syndrome ARDS, severe pneumonia, or complications following cardiac or lung surgery, with adoption concentrated in tertiary hospitals and specialized ICUs in urban regions such as São Paulo, Rio de Janeiro, and Brasília. Artificial lung devices, including portable and wearable solutions, are emerging to offer mobility, continuous oxygenation, and improved quality of life, integrating miniaturized pumps, sensors, and telemonitoring systems for home or semi-ambulatory care. Heart lung machines are widely used during cardiothoracic surgeries, ensuring oxygenation and circulation support, while bioengineered lung tissues represent an experimental and innovative segment under research, aiming to replicate natural lung function for long-term therapy or transplantation alternatives. Membrane oxygenators serve as critical components across ECMO and heart-lung systems, enabling efficient gas exchange and blood compatibility, whereas ventricular assist devices with oxygenation provide combined circulatory and respiratory support for patients with concurrent heart and lung failure. Adoption of these technologies is facilitated through hospital procurement, specialized distributors, and collaborations with research and academic institutions, supported by ANVISA approvals, clinical training programs, and post-implementation monitoring, with continuous innovation in components, smart sensors, and control units driving enhanced efficiency, safety, and patient outcomes, thereby strengthening the artificial lung ecosystem in Brazil.

In Brazil, the artificial lung market serves a range of end-users, including hospitals and medical centers, cardiac surgery centers, emergency care facilities, transplant centers, specialized intensive care units ICUs, and ambulatory surgical centers, each contributing to the adoption and utilization of advanced respiratory support technologies. Hospitals and medical centers are the primary treatment hubs, providing ECMO systems, artificial lung devices, and heart-lung machines for patients with acute and chronic respiratory failure, while leveraging skilled pulmonologists, perfusionists, and intensive care staff to ensure effective therapy. Cardiac surgery centers utilize heart-lung machines and oxygenation systems during complex cardiothoracic procedures, supporting patient circulation and oxygenation intraoperatively. Emergency care facilities and trauma units increasingly rely on portable ECMO and artificial lung devices for acute respiratory distress cases, ensuring rapid intervention and stabilization of critically ill patients. Transplant centers are key end-users for bridge-to-lung-transplant applications, using artificial lungs to sustain patients awaiting donor organs and reduce mortality. Specialized ICUs focus on high-risk respiratory failure management, employing continuous monitoring, advanced membrane oxygenators, and integrated sensor systems for optimized patient outcomes. Ambulatory surgical centers provide short-term or outpatient surgical support, integrating portable or semi-permanent oxygenation solutions for selected procedures. Adoption across these end users is facilitated by ANVISA regulatory approvals, partnerships with device manufacturers and distributors, clinical training programs, and advanced monitoring technologies, which collectively improve accessibility, enhance treatment efficacy, and strengthen the artificial lung ecosystem in Brazil by supporting timely intervention, patient safety, and optimized outcomes across critical and elective care settings.

In Brazil, the artificial lung market is segmented by application, including acute care applications, cardiac surgery support, emergency resuscitation, bridge to transplant therapy, lung transplantation support, and chronic respiratory support, reflecting diverse clinical needs across critical care, surgical procedures, and long-term respiratory management. Acute care applications dominate in intensive care units ICUs and emergency departments, addressing severe respiratory failure, ARDS, and acute complications from infections or trauma, with ECMO systems and portable oxygenators providing life saving support. Cardiac surgery support involves the use of heart-lung machines and oxygenation devices during complex cardiothoracic procedures, ensuring optimal circulation and oxygenation intraoperatively, while reducing surgical risks and improving patient outcomes. Emergency resuscitation applications utilize rapid-deployment artificial lung systems in trauma centers and emergency care facilities to stabilize critically ill patients, often in conjunction with portable ECMO or wearable oxygenation devices. Bridge to transplant therapy serves patients awaiting lung transplantation, maintaining respiratory function and reducing mortality, while lung transplantation support ensures perioperative and post-transplant oxygenation, aiding recovery and graft survival. Chronic respiratory support targets patients with long-term lung failure, including COPD, pulmonary fibrosis, and other chronic respiratory disorders, with wearable, portable, or implantable devices enabling home based care, mobility, and improved quality of life. Adoption across these applications is facilitated by hospital procurement, specialized distributors, ANVISA regulatory approvals, clinical training programs, and advanced monitoring systems, integrating smart sensors and control units to optimize oxygenation, patient safety, and therapeutic outcomes, collectively strengthening Brazil’s artificial lung ecosystem and supporting both acute intervention and long-term management of respiratory disorders.



Considered in this report
• Historic year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Artificial lungs Market with its value and forecast along with its segments
• Artificial lungs Market analysis
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Technology Type
• Extracorporeal Membrane Oxygenation (ECMO)
• Artificial Lung Devices
• Heart-Lung Machines
• Bioengineered Lung Tissues
• Membrane Oxygenators
• Ventricular Assist Devices with Oxygenation

By End-User
• Hospitals and Medical Centers
• Cardiac Surgery Centers
• Emergency Care Facilities
• Transplant Centers
• Specialized Intensive Care Units
• Ambulatory Surgical Centers

By Application
• Acute Care Applications
• Cardiac Surgery Support
• Emergency Resuscitation
• Bridge-to-Transplant Therapy
• Lung Transplantation Support
• Chronic Respiratory Support